Chimeric antigen receptor T cell therapy for pancreatic cancer: A review of current evidence
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of
malignant and non-malignant disorders. CARs are synthetic transmembrane receptors …
malignant and non-malignant disorders. CARs are synthetic transmembrane receptors …
Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping
The functional diversity of natural killer (NK) cell repertoires stems from differentiation,
homeostatic, receptor–ligand interactions and adaptive-like responses to viral infections. In …
homeostatic, receptor–ligand interactions and adaptive-like responses to viral infections. In …
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments
PR Kennedy, US Arvindam, SK Phung, B Ettestad… - Science …, 2024 - science.org
Limited oxygen (hypoxia) in solid tumors poses a challenge to successful immunotherapy
with natural killer (NK) cells. NK cells have impaired cytotoxicity when cultured in hypoxia …
with natural killer (NK) cells. NK cells have impaired cytotoxicity when cultured in hypoxia …
Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy
M Waede, LF Voss, C Kingo, JB Moeller… - Annals of Clinical …, 2024 - Wiley Online Library
Objective Anti‐CD20 therapy is a highly effective treatment for multiple sclerosis (MS). In this
study, we investigated MS‐related changes in peripheral blood mononuclear cell (PBMC) …
study, we investigated MS‐related changes in peripheral blood mononuclear cell (PBMC) …
[HTML][HTML] Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer
Z Hassouneh, ODV Noel, N Ji, ME Kim, J Svatek… - Cancers, 2024 - mdpi.com
Despite its immunogenic nature, bladder cancer (BCa) responds sub-optimally to FDA-
approved immunotherapy. Background/Objectives: We have previously shown that natural …
approved immunotherapy. Background/Objectives: We have previously shown that natural …
The G Protein–Coupled Receptor GPR56 Is an Inhibitory Checkpoint for NK Cell Migration
D Palacios, RK Majhi, EK Szabo, D Clement… - The Journal of …, 2024 - journals.aai.org
G protein coupled receptors (GPCRs) represent the largest family of surface receptors and
are responsible for key physiological functions, including cell growth, neurotransmission …
are responsible for key physiological functions, including cell growth, neurotransmission …
Highlight of 2023: Unlocking the therapeutic potential of natural killer cells-advances in adaptive functions, cellular engineering and immunotherapy.
PY Lam… - Immunology and Cell …, 2024 - europepmc.org
Natural killer (NK) cells possess potent cytotoxicity against infected and cancerous cells and
hold promise in the development of new immunotherapies. This article for the Highlights of …
hold promise in the development of new immunotherapies. This article for the Highlights of …
A Membrane Lipid Signature Unravels the Dynamic Landscape of Group 1 ILCs
In an era where the established lines between cell identities are blurred by intra-lineage
plasticity, distinguishing between stable and transitional states becomes imperative. This …
plasticity, distinguishing between stable and transitional states becomes imperative. This …
[PDF][PDF] Estrategias para la mejora de la persistencia y la eficacia de las células CAR NK para el tratamiento del mieloma múltiple refractario y en recaída Strategies to …
JE Mayoral - 2024 - docta.ucm.es
El mieloma múltiple (MM) es una neoplasia caracterizada por la proliferación clonal de
células plasmáticas patológicas, principalmente en la médula ósea. Constituye el 10% de …
células plasmáticas patológicas, principalmente en la médula ósea. Constituye el 10% de …
Estrategias para la mejora de la persistencia y la eficacia de las células CAR NK para el tratamiento del mieloma múltiple refractario y en recaída
J Encinas Mayoral - 2024 - docta.ucm.es
El mieloma múltiple (MM) es una neoplasia caracterizada por la proliferación clonal de
células plasmáticas patológicas, principalmente en la médula ósea. Constituye el 10% de …
células plasmáticas patológicas, principalmente en la médula ósea. Constituye el 10% de …